Targeting angiotensinogen (AGT) may provide a novel approach to more optimally inhibit
the renin-angiotensin-aldosterone system pathway. Double-blind, placebo-controlled …

Uncontrolled hypertension is an important contributor to cardiovascular disease. Despite the
armamentarium of antihypertensive treatments, there remains a need for novel agents …

Angiotensinogen (AGT) is the unique substrate of all angiotensin peptides. We review the
recent preclinical research of AGT antisense oligonucleotides (ASOs), a rapidly evolving …

Multiple types of renin-angiotensin system (RAS) blockers exist, allowing interference with
the system at the level of renin, angiotensin-converting enzyme, or the angiotensin II …

Blood pressure management involves antihypertensive therapies blocking the renin-
angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the …

Traditional pharmacological agents have been successfully used for the treatment of
hypertension for a number of decades. However, this therapeutic regimen has reached a …

Targeting angiotensinogen with RNA-based therapeutics is a promising new tool to treat
hypertension and diseases beyond. Their long-lasting effects are particularly exciting, and if …

The renin-angiotensin-aldosterone system (RAAS) is a well-defined pathway playing a key
role in maintaining circulatory homeostasis. Abnormal activation of RAAS contributes to …

The renin-angiotensin system plays a critical role in the control of blood pressure (BP), and
its hyperactivity is associated with the development and maintenance of hypertension …

Small interfering RNAs (siRNAs) targeting hepatic angiotensinogen (Agt) may provide long-
lasting antihypertensive effects, but the optimal approach remains unclear. Here, we …